We strive to have profound impact on decreasing mortality caused by various diseases including cancer and autoimmune diseases.
The mission of the Virginia G. Piper Center for Personalized Diagnostics is to drive the discovery and development of biomarkers for the early detection of diseases. With better disease detection and earlier treatment, we strive to have a profound impact on decreasing mortality caused by various diseases including cancer and autoimmune diseases.
Towards this end, our center and its 10 research faculty are driven by innovation and technology development, creating new tools that foster biomarker discovery. In particular, we have developed and continue to improve the NAPPA protein arrays and to couple the NAPPA technology with other technologies to better understand disease.
Besides creating tools and technology for use within the center, we also make these tools available to facilitate research projects in the wider research community. Through the plasmid repository, sequencing services and our most recent effort with the NAPPA protein array core, we have provided the tools to accelerate research in hundreds of laboratories around the world.
Joshua LaBaer, M.D., Ph.D., founder and former Director of the Harvard Institute of Proteomics (HIP), was recruited to ASU’s Biodesign Institute as the Piper Chair in Personalized Medicine and Director of the Virginia G. Piper Center for Personalized Diagnostics (VGPCPD) in 2009.
The VGPCPD has a highly multidisciplinary staff of 10 faculty including ~100 molecular biologists, cell biologists, software engineers, database specialists, bioinformaticists, biostatisticians, and automation engineers with individuals ranging from Ph.D. and M.D. degrees to graduate students, undergraduates and technical support individuals. The center uses innovation, technology, systems analysis and both clinical and fundamental medical knowledge to have a profound impact on decreasing morbidity and mortality caused by human disease.